258 related articles for article (PubMed ID: 12713066)
1. Predictive factors and selection of thymidine analogue mutations by nucleoside reverse transcriptase inhibitors according to initial regimen received.
Flandre P; Descamps D; Joly V; Meiffrédy V; Tamalet C; Izopet J; Aboulker JP; Brun-Vézinet F
Antivir Ther; 2003 Feb; 8(1):65-72. PubMed ID: 12713066
[TBL] [Abstract][Full Text] [Related]
2. The contribution of HIV fitness to the evolution pattern of reverse transcriptase inhibitor resistance.
Paintsil E; Margolis A; Collins JA; Alexander L
J Med Virol; 2006 Apr; 78(4):425-30. PubMed ID: 16482556
[TBL] [Abstract][Full Text] [Related]
3. The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations.
Miranda LR; Götte M; Liang F; Kuritzkes DR
Antimicrob Agents Chemother; 2005 Jul; 49(7):2648-56. PubMed ID: 15980332
[TBL] [Abstract][Full Text] [Related]
4. Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy.
Cozzi-Lepri A; Ruiz L; Loveday C; Phillips AN; Clotet B; Reiss P; Ledergerber B; Holkmann C; Staszewski S; Lundgren JD;
Antivir Ther; 2005; 10(7):791-802. PubMed ID: 16312176
[TBL] [Abstract][Full Text] [Related]
5. The reverse transcriptase 67N 70R 215Y genotype is the predominant TAM pathway associated with virologic failure among HIV type 1C-infected adults treated with ZDV/ddI-containing HAART in southern Africa.
Novitsky V; Wester CW; DeGruttola V; Bussmann H; Gaseitsiwe S; Thomas A; Moyo S; Musonda R; Van Widenfelt E; Marlink RG; Essex M
AIDS Res Hum Retroviruses; 2007 Jul; 23(7):868-78. PubMed ID: 17678469
[TBL] [Abstract][Full Text] [Related]
6. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.
Marcelin AG; Delaugerre C; Wirden M; Viegas P; Simon A; Katlama C; Calvez V
J Med Virol; 2004 Jan; 72(1):162-5. PubMed ID: 14635026
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.
Gómez-Cano M; Rubio A; Puig T; Pérez-Olmeda M; Ruiz L; Soriano V; Pineda JA; Zamora L; Xaus N; Clotet B; Leal M
AIDS; 1998 Jun; 12(9):1015-20. PubMed ID: 9662197
[TBL] [Abstract][Full Text] [Related]
8. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.
Miller V; Larder BA
Antivir Ther; 2001; 6 Suppl 3():25-44. PubMed ID: 11678471
[TBL] [Abstract][Full Text] [Related]
9. Increased multinucleoside drug resistance and decreased replicative capacity of a human immunodeficiency virus type 1 variant with an 8-amino-Acid insert in the reverse transcriptase.
van der Hoek L; Back N; Jebbink MF; de Ronde A; Bakker M; Jurriaans S; Reiss P; Parkin N; Berkhout B
J Virol; 2005 Mar; 79(6):3536-43. PubMed ID: 15731248
[TBL] [Abstract][Full Text] [Related]
10. Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy.
Averbuch D; Schapiro JM; Lanier ER; Gradstein S; Gottesman G; Kedem E; Einhorn M; Grisaru-Soen G; Ofir M; Engelhard D; Grossman Z
Pediatr Infect Dis J; 2006 Nov; 25(11):1049-56. PubMed ID: 17072129
[TBL] [Abstract][Full Text] [Related]
11. Short communication: selection of thymidine analogue resistance mutational patterns in children infected from a common HIV type 1 subtype G source.
Däumer M; Awerkiew S; Aragón SS; Kartashev V; Poplavskaja T; Klein R; Sichtig N; Thiele B; Lengauer T; Roomp K; Pfister H; Kaiser R
AIDS Res Hum Retroviruses; 2010 Mar; 26(3):275-8. PubMed ID: 20334563
[TBL] [Abstract][Full Text] [Related]
12. [Tenofovir DF in rescue regimens].
López Bernaldo de Quirós JC
Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():25-30. PubMed ID: 19195435
[TBL] [Abstract][Full Text] [Related]
13. Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons.
Garcia-Lerma JG; Nidtha S; Blumoff K; Weinstock H; Heneine W
Proc Natl Acad Sci U S A; 2001 Nov; 98(24):13907-12. PubMed ID: 11698656
[TBL] [Abstract][Full Text] [Related]
14. Long-term foscarnet therapy remodels thymidine analogue mutations and alters resistance to zidovudine and lamivudine in HIV-1.
Mathiesen S; Dam E; Roge B; Joergensen LB; Laursen AL; Gerstoft J; Clavel F
Antivir Ther; 2007; 12(3):335-43. PubMed ID: 17591023
[TBL] [Abstract][Full Text] [Related]
15. Human immunodeficiency virus 1 strains resistant to nucleoside inhibitors of reverse transcriptase in isolates from the Czech Republic as monitored by line probe assay and nucleotide sequencing.
Reinis M; Vandasová J; Stanková M; Linka M; Brůcková M
Acta Virol; 2001; 45(5-6):279-86. PubMed ID: 12083326
[TBL] [Abstract][Full Text] [Related]
16. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.
Stürmer M; Staszewski S; Doerr HW
Antivir Ther; 2007; 12(5):695-703. PubMed ID: 17713153
[TBL] [Abstract][Full Text] [Related]
17. Identification of insertion mutations in HIV-1 reverse transcriptase causing multiple drug resistance to nucleoside analogue reverse transcriptase inhibitors.
Sugiura W; Matsuda M; Matsuda Z; Abumi H; Okano A; Oishi T; Moriya K; Yamamoto Y; Fukutake K; Mimaya J; Ajisawa A; Taki M; Yamada K; Nagai Y
J Hum Virol; 1999; 2(3):146-53. PubMed ID: 10413366
[TBL] [Abstract][Full Text] [Related]
18. Thymidine-analog and multi-nucleoside resistance mutations are observed in both zidovudine-naive and zidovudine-experienced subjects with viremia after treatment with stavudine-containing regimens.
Ross L; Henry K; Paar D; Salvato P; Shaefer M; Fisher R; Liao Q; St Clair M
J Hum Virol; 2001; 4(4):217-22. PubMed ID: 11694850
[TBL] [Abstract][Full Text] [Related]
19. Phenotypic and genotypic resistance to nucleoside reverse transcriptase inhibitors in HIV-1 clinical isolates.
Lafeuillade A; Poggi C; Hittinger G; Chadapaud S
HIV Med; 2001 Oct; 2(4):231-5. PubMed ID: 11737402
[TBL] [Abstract][Full Text] [Related]
20. Broad nucleoside-analogue resistance implications for human immunodeficiency virus type 1 reverse-transcriptase mutations at codons 44 and 118.
Romano L; Venturi G; Bloor S; Harrigan R; Larder BA; Major JC; Zazzi M
J Infect Dis; 2002 Apr; 185(7):898-904. PubMed ID: 11920313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]